Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

被引：0
|
作者：
Craig Leonardi
Kristian Reich
Peter Foley
Hideshi Torii
Sascha Gerdes
Lyn Guenther
Melinda Gooderham
Laura K. Ferris
Christopher E. M. Griffiths
Hany ElMaraghy
Heidi Crane
Himanshu Patel
Russel Burge
Gaia Gallo
David Shrom
Ann Leung
Chen-Yen Lin
Kim Papp
机构：
[1] Central Dermatology,Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing
[2] University Medical Center Hamburg-Eppendorf,St. Vincent’s Hospital Melbourne and Probity Medical Research, Skin Health Institute
[3] Skinflammation® Center,Division of Dermatology
[4] The University of Melbourne,Psoriasis
[5] Tokyo Yamate Medical Center,Center at the Department of Dermatology
[6] University Medical Center Schleswig-Holstein,Dermatology Centre, Salford Royal Hospital
[7] Guenther Dermatology Research Centre,undefined
[8] SkiN Centre for Dermatology and Probity Medical Research,undefined
[9] University of Pittsburgh Medical Center,undefined
[10] University of Manchester,undefined
[11] Eli Lilly and Company,undefined
[12] Lilly Corporate Center,undefined
[13] Syneos Health,undefined
[14] K. Papp Clinical Research and Probity Medical Research Inc.,undefined
来源：
Dermatology and Therapy | 2020年 / 10卷
关键词：
Ixekizumab; Long-term efficacy; Long-term safety; Maintain; Psoriasis; Quality of life; 5 years;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：431 / 447
页数：16
相关论文
共 50 条
  • [21] Ixekizumab sustains high efficacy and a favorable safety profile in burdensome areas in patients with moderate-to-severe psoriasis: 5-year results from UNCOVER-2
    Papp, Kim
    Blauvelt, Andrew
    Puig, Luis
    Elmaraghy, Hany
    See, Kyoungah
    McKean-Matthews, Missy
    Crane, Heidi
    Garrelts, Alyssa
    Leonardi, Craig
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB50 - AB50
  • [22] Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
    Andrew Blauvelt
    Kim A. Papp
    Christopher E. M. Griffiths
    Luis Puig
    Jamie Weisman
    Yves Dutronc
    Lisa Farmer Kerr
    Dapo Ilo
    Lotus Mallbris
    Matthias Augustin
    American Journal of Clinical Dermatology, 2018, 19 : 457 - 457
  • [23] Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and-3)
    Blauvelt, Andrew
    Papp, Kim A.
    Griffiths, Christopher E. M.
    Puig, Luis
    Weisman, Jamie
    Dutronc, Yves
    Kerr, Lisa Farmer
    Ilo, Dapo
    Mallbris, Lotus
    Augustin, Matthias
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2017, 18 (02) : 273 - 280
  • [24] Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)
    Papp, Kim A.
    Gerdes, Sascha
    Leonardi, Craig L.
    Elmaraghy, Hany
    See, Kyoungah
    McKean-Matthews, Missy
    Konicek, Bruce W.
    Crane, Heidi M.
    Eastman, William
    JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (08) : 880 - 887
  • [25] Efficacy and safety of ixekizumab in patients with moderate-to-severe plaque psoriasis with and without psoriatic arthritis at baseline: Results from UNCOVER studies through 5 years
    Gottlieb, Alice
    de Vlam, Kurt
    Wang, Yan
    See, Kyoungah
    Bolce, Rebecca
    Wolf, Eric
    Burge, Russel
    Patel, Himanshu
    Merola, Joseph F.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB70 - AB70
  • [26] Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, phase III clinical trial (UNCOVER-3)
    Blauvelt, Andrew
    Gooderham, Melinda
    Iverson, Lars
    Ball, Susan
    Agada, Noah
    Zhang, Lu
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB112 - AB112
  • [27] Ixekizumab impact on the skin-related relationship problems of patients with moderate-to-severe plaque psoriasis: integrated results from three Phase 3 trials (UNCOVER-1,-2,-3)
    Warren, R. B.
    Cather, J.
    Ohtsuki, M.
    Bleakman, A. Potts
    Burge, R.
    Zhu, B.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 77 - 78
  • [28] A Phase 3 Trial Comparing Ixekizumab with Placebo and Etanercept for Moderate-to-Severe Plaque Psoriasis: Results from the 12 Week Induction Period of UNCOVER-2
    Griffiths, C. E. M.
    Leutz, A.
    Reich, K.
    Lebwohl, M.
    van de Kerkhof, P.
    Paul, C.
    Menter, A.
    Cameron, G. S.
    Erickson, J.
    Zhang, L.
    Secrest, R.
    Ball, S.
    Braun, D.
    Osuntokun, O. O.
    Heffernan, M.
    Nickoloff, B. J.
    Papp, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 3 - 3
  • [29] Ixekizumab impact on itch severity compared to etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with moderate-to-severe plaque psoriasis
    Kimball, Alexa Boer
    Nikai, Enkeleida
    Zhu, Baojin
    Carlier, Hilde
    Yosipovitch, Gil
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S19 - S19
  • [30] A phase 3 trial comparing ixekizumab with placebo and etanercept for moderate-to-severe plaque psoriasis: Results from the 12 week induction period of UNCOVER-2
    Griffiths, Christopher E.
    Reich, Kristian
    Lebwohl, Mark
    Van de Kerkhof, Peter
    Paul, Carle
    Menter, Alan
    Carlier, Hilde
    Cameron, Gregory
    Erickson, Janelle
    Zhang, Lu
    Secrest, Roberta
    Ball, Susan
    Braun, Daniel
    Osuntokun, Olawale
    Heffernan, Michael
    Nickoloff, Brian
    Papp, Kim
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S17 - S17
12345